Business Wire

Berry Consultants Releases FACTS 8 Clinical Trial Simulator

Share

FACTS 8 introduces support for Ordinal endpoints and a new “Quick Start” feature

Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/

FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements:

  • Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis.
  • A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provides for more customized adaptive designs.

“Ordinal endpoints are ubiquitous in clinical trials and the ability to optimize the analyses and design for trials utilizing them is becoming increasingly important,” said Scott Berry, PhD, President and Senior Statistical Scientist at Berry Consultants. “With FACTS 8, we’re giving researchers a unified platform to evaluate and compare analytical methods for these endpoints — from dichotomization, non-parametric Wilcoxon tests, proportional odds testing, Bayesian Dirichlet models, to utility weighting. This capability allows teams to directly compare performance, make better design choices, and ultimately improve clinical research.”

The Ordinal Endpoint Module in FACTS 8 supports simulation of one-, two-, or multi-arm trials and includes the full range of adaptive design features — early stopping, arm dropping, and response-adaptive randomization.

“This release not only extends the power and range of FACTS, but also makes simulation of conventional trials faster and easier,” added Tom Parke, Director of Software Solutions at Berry Consultants. “The new Quick Start feature allows users to set up and run standard designs in minutes, while retaining the same detailed simulation engine that powers our most advanced adaptive trials.”

With these enhancements, FACTS continues to reflect Berry Consultants’ philosophy that clinical trial simulation should be intuitive, transparent, and comprehensive. FACTS enables users to specify and compare designs across the entire range of trial types — from simple fixed designs to the most innovative adaptive platforms — supporting smarter and more efficient clinical development.

About Berry Consultants

Berry Consultantsis an internationally recognized leader in the design, simulation, and implementation of innovative clinical trials. Founded in 2000, the company specializes in Bayesian and adaptive clinical trials and provides both consulting expertise and software solutions to pharmaceutical, biotechnology, and academic partners worldwide. Through its flagship FACTS software platform, Berry Consultants empowers researchers to explore, optimize, and execute trial designs that improve efficiency, ethics, and scientific insight across therapeutic areas. www.berryconsultants.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023501254/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release

ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c

Mouser Electronics Explores the Future of Advanced Air Mobility and Its Impact on Design4.11.2025 17:37:00 CET | Press release

Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, released its latest installment of the Empowering Innovation Together (EIT) technology series, Urban Transport Takes Flight, examining the emerging sector of Advanced Air Mobility (AAM). This series details the technology behind electric vertical takeoff and landing (eVTOL) vehicles, the challenges of infrastructure for city deployment, and the hydrogen fuel cell solutions that power the future of urban transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104083206/en/ Mouser explores the technology behind urban air mobility (UAM) vehicles, the challenges of infrastructure, and the fuel solutions that are powering the future of urban transport. The path for Urban Air Mobility (UAM) to transition from futuristic concept to scalable reality is constrained by barriers in form, power, and

Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology4.11.2025 17:02:00 CET | Press release

Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/ Nanobubble Technology in Oil & Gas: Performance Advantages Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability. Unlike traditional flotation systems that rely on

GD32 MCU Family Expands High-Performance Portfolio with New GD32F503/505 Series MCU4.11.2025 17:00:00 CET | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced the official launch of the GD32F503/505 high-performance series of 32-bit general-purpose microcontrollers. This release significantly strengthens its product portfolio based on the Arm® Cortex®-M33 core. Built on the Arm® v8-M architecture, the series operates at a frequency of 280 MHz and features flexible memory configurations and built-in security functions. It is well-suited for a wide range of applications, including digital power supplies, industrial automation, motor control, robotic vacuum cleaners, BMS, humanoid robots, and more. The GD32F503/505 series MCUs are now available as samples and development boards are available on request, with mass production due to begin in December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104783233/en/ Higher Frequency for S

Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release

Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye